Inming Biotech

Inming Biotech (炎明生物) is a Chinese biotech startup focused on developing first-in-class drugs, founded as a FreeS Fund (峰瑞资本) angel-round portfolio company . The company completed a 700 million RMB Series A round in 2023 led by SDIC Venture Capital (国投创业), with co-lead China Venture Capital Fund (国风投基金) and follow-on from FreeS Fund and other prior investors . FreeS Fund continued to participate in a subsequent Series A+ round of several hundred million RMB in mid-2024 . The firm is part of FreeS Fund's broader biotech portfolio alongside companies such as Jingtai Technology, Xinsu Technology, and Kein Biology .